DFDA

Anti-fibrotic agents (e.g., Pirfenidone, Nintedanib)

Treatment for Silicosis

Typical Dosage: Pirfenidone 2403mg/day, Nintedanib 150mg BID

Effectiveness
25%
Safety Score
35%
Clinical Trials
4
Participants
80

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
Pirfenidone 2403mg/day, Nintedanib 150mg BID
Time to Effect
6-12 months (to slow decline)
Treatment Duration
lifetime
Evidence Quality
VERY-LOW
Confidence Score
30%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100,000
Monitoring:$750
Side Effect Mgmt:$1,500
Total Annual:$102,250
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$681,667
Anti-fibrotic agents (e.g., Pirfenidone, Nintedanib) Outcomes

for Silicosis

Efficacy Outcomes
Overall Effectiveness
+25%
Response Rate
+15%
Common Side Effects
Diarrhea
+65%
Nausea
+35%
Rash/Photosensitivity
+15%
Liver enzyme elevation
+7%

Sources:

nih.gov
frontiersin.org
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov